Lv6
2748 积分 2021-03-24 加入
ADHESION, CELL–CELL | Vascular
6天前
已完结
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
7天前
已完结
Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes
18天前
已完结
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
28天前
已完结
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
28天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
28天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
28天前
已完结
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
28天前
已完结
Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease
1个月前
已完结
Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
1个月前
已完结
皖公网安备34019202002308
